Co-Diagnostics, Inc.
(NASDAQ CM: CODX)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Co-Diagnostics, Inc. ("Co-Diagnostics") on behalf of stockholders. A class action complaint has been filed against Co-Diagnostics. The complaint alleges that defendants made continual, knowing, and willful misstatements about their main product, a Covid-19 diagnostic test, to pump of the price of Co-Diagnostics' stock while the officers and directors exercised low priced options and dumped their stock into the market. The complaint alleges that defendants' fraudulent misstatements, and disregard for the basic scientific principles that make the falsity of their statements clear in retrospect, cost investors to lose millions of dollars.